Retraction note: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment (Cancer Chemotherapy and Pharmacology, (2022), 89, 6, (761-772), 10.1007/s00280-022-04428-0)

Mototsugu Oya, Shuichi Kaneko, Tsuneo Imai, Toshiaki Tsujino, Toshiyuki Sunaya, Yutaka Okayama

Research output: Contribution to journalComment/debatepeer-review

Abstract

The Authors have retracted this article. After publication the authors found a flaw in the way the raw data was handled for this study and found that the data analysis was incomplete. The authors re-analysed the data and found that the conclusions initially drawn from the results were no longer supported. The authors, therefore, no longer have confidence in the results presented in this article. All authors agree to this retraction.

Original languageEnglish
Pages (from-to)523
Number of pages1
JournalCancer Chemotherapy and Pharmacology
Volume93
Issue number5
DOIs
Publication statusPublished - 2024 May

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Retraction note: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment (Cancer Chemotherapy and Pharmacology, (2022), 89, 6, (761-772), 10.1007/s00280-022-04428-0)'. Together they form a unique fingerprint.

Cite this